Ace Therapeutics news
Ace Therapeutics, a biotechnology company pioneering novel central nervous system (CNS) delivery solutions, today announced the release of its BBBporter™ technology platform. This innovative platform is specifically designed to overcome the primary challenge in treating brain diseases: the blood-brain barrier (BBB). By leveraging a suite of biomimetic and AI-powered technologies, BBBporter™ enables the efficient transport of
Ace Therapeutics, a preclinical contract research provider dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and expedite the discovery of innovative therapeutic solutions.
Depression is a
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches.
Diabetes mellitus, a chronic condition characterized by elevated blood sugar levels, affects millions worldwide and poses serious health risks including cardiovasc
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease.
Glaucoma is a group of eye conditions that damage the op
Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery.
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for innovative research and therapeutic solutions. Cardiovascular disease models are ess